Bevacizumab Purification by Peptide Affinity Chromatography

GABRIELA R. BARREDO; SILVANA L. GIUDICESSI; MARÍA C. MARTÍNEZ-CERÓN; SOLEDAD L. SAAVEDRA; GUSTAVO MAHLER; FERNANDO ALBERICIO; OSVALDO CASCONE; SILVIA A. CAMPERI

Proceedings of the 35th European Peptide Symposium

European Peptide Society

Año: 2018; p. 130 - 132

Therapeutic Monoclonal Antibodies (mAbs) are widely used in the treatment of many diseases. Bevacizumab (trade name: Avastin) inhibits the vascular endothelial growth factor and hence the angiogenesis process. It is used in brain, breast, colorectal, lung and renal cancer treatments (1). Due to its parenteral administration,its degree of purity must be extremely high. Nowadays, that is achieved by affinity chromatography (AC) with immobilized protein A, a highly expensive ligand that increases the cost of the purification process. On the other hand, short peptides are ideal ligands for AC due to their higher stability, easier synthesis and lower cost in comparison to protein A (2). In this work, a short peptide ligand with affinity for Bevacizumab was selected from a peptide library.